9.271USD+5.23%Mkt Cap: 767.93M USDP/E: —Last update: 2026-06-01
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product cand…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap767.93M USD
Enterprise Value525.18M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-247.30M USD
Revenue/Share—
Last Price9.271 USD
Fiscal Year EndMar 2025
MR QuarterDec 2025
Employees479
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS76029N1063
Valuation
P/E (Trailing)—
P/E (Forward)-4.21
PEG—
EV/EBITDA-1.65
EV/Revenue—
P/S—
P/B3.29
EPS (TTM)-3.44
EPS (Forward)-2.06
52W Range
1.50066% of range13.24
52W High13.24 USD
52W Low1.500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-59.47%
ROA-44.85%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-192.25M USD
CapEx (TTM)6.69M USD
FCF Margin—
FCF Yield-22.50%
Net Debt-192.79M USD
Net Debt/EBITDA0.60
Balance Sheet
Debt/Equity0.18
Current Ratio5.60
Quick Ratio5.43
Book Value/Sh2.644 USD
Cash/Share3.259 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.500 USD
Target Range1.000 USD – 10.00 USD
# Analysts6
Ownership
Shares Out.82.57M
Float58.46M
Insiders2.62%
Institutions97.48%
Short Interest
Short Ratio2.8d
Short % Float51.35%
Short % Out.28.65%
Shares Short23.66M
Short (prev mo.)18.43M
Technical
SMA 504.721 (+96.4%)
SMA 2006.789 (+36.5%)
Beta0.12
S&P 52W Chg27.70%
Avg Vol (30d)8.37M
Avg Vol (10d)4.60M
Technical Indicators
RSI (14)76.0
MACD0.5303
MACD Signal0.1934
MACD Hist.+0.3369
BB Upper7.174 USD
BB Middle4.513 USD
BB Lower1.852 USD
BB Width117.91%
ATR (14)0.8176 USD
Vol Ratio (20d)7.52x